From the Journals

Low-carb diets boost diabetes remission rates, at least short term


 

VLCDs: Adherence Is key

Finally, the team looked at weight loss achieved with VLCDs.

VLCDs were less effective for weight loss at 6 months than less restrictive LCDs. However, this effect was explained by diet adherence, the researchers noted.

Restricting the analysis to “credible” studies, VLCDs were associated with a larger “clinically important” weight-loss versus control diets when patients were highly adherent to the diet, at a mean reduction of 4.47 kg (9.9 lb) versus a mean increase of 0.55 kg (1.2 lb) among patients who were less adherent.

The team noted that their review has a number of limitations, not least of which is the definition of diabetes remission used, which “is the subject of considerable debate,” as well as the safety concerns raised over LCDs.

Given the latter concerns, “clinicians might consider short-term LCDs for management of type 2 diabetes, while actively monitoring and adjusting diabetes medication as needed,” they concluded.

This study was funded in part by Texas A&M University. One coauthor reported receiving funding from Texas A&M AgriLife Research for a separate research project. Dr. Brinkworth is author of the book “The CSIRO Low Carb Diet,” but does not receive financial royalties or funds either directly or indirectly.

A version of this article first appeared on Medscape.com.

Pages

Recommended Reading

Patient health suffers amid pandemic health care shortages
Journal of Clinical Outcomes Management
Peripheral neuropathy tied to mortality in adults without diabetes
Journal of Clinical Outcomes Management
Sac/val heart failure benefit extends to diabetes patients
Journal of Clinical Outcomes Management
FDA okays first generic injected glucagon for hypoglycemia
Journal of Clinical Outcomes Management
Endocrine Society calls for action to reduce insulin costs
Journal of Clinical Outcomes Management
To fast or not? The new dieting dilemma
Journal of Clinical Outcomes Management
Sotagliflozin’s trial data receives FDA welcome for NDA filing
Journal of Clinical Outcomes Management
Pressure builds on CDC to prioritize both diabetes types for vaccine
Journal of Clinical Outcomes Management
Biomarker HF risk score envisioned as SGLT2 inhibitor lodestar in diabetes
Journal of Clinical Outcomes Management
Further warning on SGLT2 inhibitor use and DKA risk in COVID-19
Journal of Clinical Outcomes Management